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Cardiotoxicity associated with the anticancer drug doxo-
rubicin (DOX, trade name Adriamycin) is typically attrib-
uted to myocardial oxidative stress as DOX undergoes 
redox cycling at complex I of the electron transport chain. 
This cardiotoxicity can present itself acutely or chronically. 
DOX-induced acute cardiotoxicity can be detected minutes 
to hours after DOX administration in the form of arrhyth-
mias and hypotension.1 Acute DOX cardiotoxicity may also 
be detected days following administration in the form of 
reduced left ventricular fractional shortening and devel-
oped pressure.2,3 Chronic cardiotoxicity, on the other hand, 
may set in weeks, months, or years following the comple-
tion of DOX treatment,4,5 and in many cases, the symptoms 
mimic those of dilated cardiomyopathy or congestive heart 
failure.6,7
Although DOX treatment can lead to severe cardiotoxic-
ity, it is one of the most effective antineoplastic agents 
available. As a result, numerous attempts have been made to 
develop interventions that minimize its side effects. Studies 
examining the effectiveness of these interventions, how-
ever, typically investigate only acute cardiotoxicity.8-11 
Such interventions targeted against acute cardiotoxicity 
include the use of iron chelators,12 antioxidants,13,14 statins,15 
and amino acid supplementation.16,17 These acute DOX car-
diotoxicity studies have limited clinical application, how-
ever, since chronic forms of DOX cardiotoxicity can 
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Abstract
Acute doxorubicin (DOX) cardiotoxicity can be attenuated by exercise preconditioning, but little is known of whether 
this cardioprotection continues beyond 10 days post-DOX administration. The purpose of this study was to determine 
the effects of exercise preconditioning on early chronic DOX-induced cardiotoxicity. Male rats were randomly assigned to 
sedentary, treadmill, or wheel running groups. Treadmill and wheel running animals participated in a progressive treadmill 
training protocol or voluntary wheel running, respectively, for 10 weeks. Following the intervention, animals were further 
randomized to receive either DOX (sedentary + DOX, treadmill + DOX, wheel running + DOX) or saline (sedentary + 
saline, treadmill + saline, wheel running + saline). All animals then remained sedentary for 4 weeks. A 22% reduction in 
fractional shortening was observed in left ventricles from previously sedentary animals receiving DOX when compared 
with sedentary + saline. This degree of decline was not observed in treadmill + DOX and wheel running + DOX. Sedentary 
+ DOX possessed significantly depressed mitral and aortic valve blood flow velocities when compared with sedentary + 
saline, but these decrements were not observed in treadmill + DOX and wheel running + DOX. Ex vivo analysis revealed 
that left ventricular developed pressure and maximal rate of pressure development were significantly lower in sedentary 
+ DOX when compared to sedentary + saline. Treadmill and wheel running prior to DOX treatment protected against 
these decrements. Exercise cardioprotection was associated with preserved myosin heavy chain but not sarcoendoplasmic 
reticulum Ca2+ ATPase 2a expression. In conclusion, 10 weeks of prior exercise protected against early chronic DOX 
cardiotoxicity suggesting that training status may be a determining factor in the degree of late-onset cardiotoxicity 
experienced by cancer patients undergoing treatment with DOX.
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manifest in the absence of severe acute cardiotoxicity.18,19 
Our laboratory previously reported that 1 mg/kg DOX 
administered daily for 10 consecutive days (10 mg/kg 
cumulative) promoted a later onset (ie, weeks posttreat-
ment) and more severe form of cardiac dysfunction than a 
bolus 10 mg/kg DOX dose in male rats,7 representing a 
model of “early chronic” DOX cardiotoxicity, which sets 
in weeks to months following cessation of treatment.5 
Acute DOX cardiotoxicity is reversible and controllable 
clinically whereas chronic DOX cardiotoxicity is irrevers-
ible and has a much poorer prognosis.20 Therefore, a need 
exists to develop interventions that provide lasting protection 
against chronic DOX cardiotoxicity.
DOX cardiotoxicity is multifaceted, and many traditional 
cardioprotective approaches typically target only one of the 
many possible mechanisms of its toxicity. A number of mech-
anisms have been proposed to explain DOX cardiotoxicity, 
including the generation of reactive oxygen species (ROS), 
apoptosis, DNA interference, and metabolic alterations 
(for review see Simunek et al5), and these mechanisms 
contribute to impaired systolic and diastolic cardiac func-
tion. DOX-induced systolic dysfunction has often been 
attributed to altered expression of cardiac myosin heavy 
chain (MHC) isoforms since DOX administration promotes a 
downregulation of α-MHC with a concurrent upregulation of 
β-MHC.3,21,22 Cardio myocytes express both the fast ATPase 
activity α-MHC isoform and the slow ATPase activity β-
MHC isoform, and their relative expression contributes to 
contractile performance as cardiomyocytes expressing 
primarily α-MHC have been shown to possess a 2-fold 
greater power output than cardiomyocytes expressing primar-
ily β-MHC.23 DOX-induced diastolic dysfunction, on the 
other hand, is often attributed to depressed cytosolic Ca2+ 
recycling.24,25 This impaired Ca2+ handling is typically a 
result of reduced sarcoendoplasmic reticulum Ca2+ 
ATPase 2a (SERCA2a) expression26,27 as this pump is 
responsible for the majority of Ca2+ recycling from the 
cytosol into the sarcoplasmic reticulum (SR). Because the 
etiology of DOX cardiotoxicity is so complex, an approach 
that targets multiple mechanisms could prove to be valuable 
clinically.
Exercise training is one such intervention that shows 
promise in combating multiple aspects of DOX-induced 
cardiotoxicity by improving antioxidant status,28 attenuat-
ing apoptotic pathways,29 and preserving contractile protein 
expression.21 In addition, our laboratory has reported that 
long-term exercise preconditioning protected against early-
onset DOX cardiotoxicity up to 10 days following treat-
ment.2,3 However, at this time it is unclear how long the 
protective effects of exercise preconditioning persist after 
DOX treatment is completed. The importance of this is 
apparent considering the fact that the clinical presentation 
of chronic DOX-induced cardiac dysfunction is more 
severe than the acute dysfunction (ie, reversible cardiac 
dysfunction function vs irreversible cardiac dysfunction). 
Therefore, the purpose of this study was to examine the 
lasting effects of exercise preconditioning on chronic 
DOX cardiotoxicity. In addition, cardiac MHC and 
SERCA2a expression was analyzed to investigate possible 
mechanisms that may explain any observed cardioprotec-
tion. It was hypothesized that exercise preconditioning 
would attenuate DOX-induced early chronic cardiotoxicity 
by attenuating MHC and SERCA2a alterations.
Materials and Methods
Animals and Animal Care
All procedures were approved by the Institutional Animal 
Care and Use Committee and were in compliance with the 
Animal Welfare Act guidelines. Male Sprague–Dawley rats 
(~250 g) were purchased from Harlan (Indianapolis, IN) 
and were housed in an environmentally controlled facility 
on a 12:12 light:dark cycle and were provided chow and 
water ad libitum. Initially, rats were randomly assigned to 
the sedentary group (SED, n = 25), treadmill training group 
(TM, n = 29), or voluntary wheel running group (WR, n = 
40).
Exercise Preconditioning
SED animals remained in their cages throughout the 
10-week treatment period. TM animals ran on a motorized 
rodent treadmill 5 days per week for 10 weeks using a pro-
gressive treadmill training protocol (Table 1). This tread-
mill protocol was shown previously to attenuate 
DOX-induced cardiac dysfunction 5 and 10 days following 
drug administration.3 WR animals were housed individually 
in cages fitted with voluntary running wheels and were 
allowed 24-hour access to the wheels for 10 weeks. Running 
wheel activity data were collected using a Vital View data 
acquisition system (MiniMitter, Bend, OR).
Doxorubicin Treatment
Twenty-four hours after the completion of the 10-week 
exercise preconditioning period, SED, TM, and WR ani-
mals were randomly assigned to receive either DOX or 
saline (SAL) injections. TM + DOX (n = 17), WR + DOX 
(n = 23), and SED + DOX (n = 14) received 1 mg/kg DOX 
intraperitoneally (i.p.) daily for 10 consecutive days for a 
cumulative dose of 10 mg/kg. Injections were performed 
using a stock solution of 2 mg/mL, which resulted in injec-
tion volumes of approximately 0.2 to 0.4 mL. This daily 
dosing scheme has been shown previously to promote 
later onset cardiac dysfunction (ie, early chronic cardiotox-
icity) while improving survival when compared with a 
bolus dose.7 Animals in SED + SAL (n = 11), TM + SAL (n 
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isolated and cannulated, and flow was redirected from the 
aorta to the left atria to initiate the working heart mode. 
Following stabilization, a standardized preload and after-
load was obtained for each heart (10 cm H
2
O and 100 cm 
H
2
O, respectively). A micotip pressure transducer (SPR-
671; 1.4 F; Millar Instruments Inc, Houston, TX) was 
inserted into the LV cavity for acquisition of developed 
pressure (LVDP), maximal rate of pressure development 
(+dP/dt), and maximal rate of pressure decline (−dP/dt). 
For all data collection, hearts were paced at 300 bpm 
using a stimulus isolator (ADInstruments, Colorado 
Springs, CO). Following the isolated working heart prepa-
ration, hearts were dissected, and the LV was isolated, snap 
frozen in liquid N
2
, and stored at −80°C for ensuing bio-
chemical analysis.
Myosin Heavy Chain
LV homogenates were analyzed for MHC isoform 
expression using SDS-PAGE (sodium dodecyl sulfate– 
polyacrylamide gel electrophoresis) according to Talmadge 
and Roy30 and described previously by our laboratory.3 
Frozen LVs were minced and homogenized in homogeniz-
ing buffer (250 mM sucrose, 100 mM KCl, 5 mM EDTA, 
and 20 mM Tris-Base, pH 6.8) and centrifuged at 1000g to 
isolate myofibrils. Myofibrils were then washed in washing 
buffer (175 mM KCl, 0.5% Triton X-100, 2 mM EDTA, 
and 20 mM Tris-Base, pH 6.8) twice to remove contaminat-
ing ATPases. Myofibrils were then resuspended in final 
resuspension buffer (150 mM KCl and 20 mM Tris-Base, 
pH 7.0) and protein concentration was determined using the 
Bradford method.31 Protein (9.75 µg) was loaded onto an 
8% polyacrylamide separating gel with a 4% polyacryl-
amide stacking gel and run at 100 V (Sure-Lock electro-
phoresis unit, Invitrogen Corporation, Carlsbad, CA) until 
tracking dye reached bottom of the gel. Gels were stained 
with Coomassie blue, and α- and β-isoforms were analyzed 
using densitometry.
SERCA2a
Frozen LVs were minced and homogenized in 10 volumes 
of RIPA buffer containing a protease inhibitor cocktail 
(Sigma-Aldrich, St Louis, MO) using a glass tissue 
grinder. Cell membranes were further disrupted using soni-
cation. Homogenates were centrifuged for 10 minutes at 10 
000g and the supernatant was recovered for analysis. 
Protein concentration was determined using the Bradford 
method.31 All samples were then normalized to 3 mg/mL 
protein with RIPA buffer and diluted to 1.5 mg/mL with 
Lammli sample buffer. 30 µg of protein (ie, 20 µL) from 
each sample were loaded onto lanes of 10% polyacryl-
amide gels and separated using SDS-PAGE. Proteins were 
transferred to nitrocellulose membranes and incubated with a 
Table 1. Progressive Treadmill Training Protocol
Week
 1 2 3 4 5 6 7 8 9 10
Speed (m/min) 20 25 25 30 30 30 30 30 30 30
Incline (°)  0  0  0  3  6  9 12 15 18 18
Duration (min) 20 30 30 60 60 60 60 60 60 60
= 12), and WR + SAL (n = 17) groups received daily i.p. 
injections of 0.9% saline for 10 days at equivalent volumes 
to that of DOX. Following the 10-day DOX/SAL treatment 
regimen, all animals remained sedentary for 4 weeks.
Echocardiography
Four weeks following the completion of DOX treatment, 
cardiac function was assessed in vivo using transthoracic 
echocardiography using a commercially available echocar-
diographic system (Toshiba Nemio 30; 10 MHz pediatric 
transducer) as described previously by our laboratory.7 
Briefly, the anterior and left lateral thoracic region of 
sedated animals (ketamine 40 mg/kg i.p.) was shaved, and 
the transducer was positioned to obtain left ventricular (LV) 
M-mode images for determination of septal wall thickness 
at systole (SWs) and diastole (SWd), posterior wall thick-
ness at systole (PWs) and diastole (PWd), LV end-systolic 
diameter (LVDs) and LV end-diastolic diameter (LVDd). In 
addition, the aforementioned variables were used to calcu-
late fractional shortening (FS), LV mass, and relative wall 
thickness (RWT).
Pulsed wave Doppler images were then acquired from 
an apical view to obtain profiles of mitral and aortic valve 
blood flow. Measurements taken at the mitral valve yielded 
maximal blood flow velocity (MV
max
), and mean blood 
flow velocity (MV
mean
). Similarly, measurements taken at 
the aortic valve yielded maximal blood flow velocity 
(AV
max
) and mean blood flow velocity (AV
mean
). For all 
echocardiography measures, data from 3 consecutive car-
diac cycles, when possible, were obtained and averaged for 
each animal.
Isolated Working Heart
On completion of echocardiographic procedures, hearts 
were perfused using an isolated working heart preparation 
as described previously.3 Animals were anesthetized with 
heparanized (500 U) sodium pentobarbital (50 mg/kg). 
Once a tail-pinch reflex was absent, the heart was rapidly 
excised, the aorta was cannulated, and retrograde perfusion 
ensued with Krebs-Hanseleit buffer (120 mM NaCl, 5.9 
mM KCl, 2.5 mM CaCl
2
, 1.2 mM MgCl
2
, 25 mM 
NaHCO
3
, 17 mM glucose, and 0.5 mM EDTA, pH 7.4) aer-




. The pulmonary vein was then 
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primary antibody specific to SERCA2a (AbCam, Cambridge, 
MA). The primary antibody was then probed with an alka-
line phosphatase conjugated secondary antibody 
(WesternBreeze, Invitrogen, Carlsbad, CA) and incubated 
with a chromogenic substrate (BCIP/NBT) until bands 
developed on the membrane. Protein band intensity was 
analyzed using densitometry.
Statistical Analysis
All results are expressed as mean ± standard error of the 
mean (mean ± SEM). A one-way analysis of variance was 
performed to identify group differences between SED + 
SAL, SED + DOX, TM + SAL, TM + DOX, WR + SAL, 
and WR+DOX. If a significant F-value was observed, 
Tukey’s post hoc testing was done to identify where differ-
ences existed. Additionally, WR + SAL and WR + DOX 
weekly wheel run distances were compared using t tests. For 
all procedures, significance was set at the α = .05 level.
Results
General Observations
During the 10-week exercise preconditioning period, no 
significant weekly wheel running differences were observed 
between WR + SAL and WR + DOX (P > .05). Additionally, 
post hoc testing revealed that no significant differences 
existed between any of the variables from SED + SAL, TM 
+ SAL, and WR + SAL (P > .05) suggesting that the 10-week 
treadmill and wheel running preconditioning treatments 
alone had no effect on cardiac function, MHC distribution, 
or SERCA2a expression when analyzed 4 weeks post–
SAL administration. Therefore, significant differences 
reported hereafter are comparisons between SED + SAL, 
SED + DOX, TM + DOX, and WR + DOX, which represent 
the aims of this study.
Survival rates between DOX-treated groups are also 
worthy of note. In SED + DOX, a 60% survival rate was 
observed 4 weeks post–DOX administration resulting in n 
= 9 for cardiac function and biochemical analyses. In com-
parison, TM + DOX had a 94% survival rate and WR + 
DOX had a 74% survival rate resulting in n = 16 and n = 
17, respectively, for cardiac function and biochemical 
analyses.
Echocardiography
Table 2 contains cardiac geometry data derived from 
M-mode images obtained during echocardiography. SED + 
DOX possessed significantly lower SWs and SWd when 
compared with SED + SAL, TM + DOX, and WR + DOX 
(P < .05) suggesting that exercise preconditioning preserved 
DOX-induced septal wall thinning. However, PWs was 
significantly lower in all DOX-treated groups when com-
pared with SED + SAL (P < .05) regardless of sedentary or 
exercise preconditioning treatments. PWd was significantly 
lower in SED+DOX and TM + DOX when compared with 
SED + SAL (P < .05), but this PWd decrement was not 
observed in WR + DOX (P > .05). No between-group dif-
ferences were observed in LVDs or LVDd (P > .05), but 
RWT and LV mass were found to be significantly lower in 
SED + DOX when compared with SED + SAL, TM + 
DOX, and WR + DOX (P < .05). A 21% decrease in FS 
was observed in SED + DOX when compared with SED + 
SAL, which was found to be significant (Figure 1, P < .05). 
Although TM + DOX and WR + DOX possessed a 13% and 
15% decrease in FS, respectively, when compared with SED 
+ SAL, these differences were not found to be significant 
(P > .05).
Mitral valve blood flow velocities are illustrated in Figure 
2. When compared with SED + SAL, SED + DOX possessed 
a 37% reduction in MV
max
 (P < .05, Figure 2A), and although 
TM + DOX and WR + DOX had 12% and 14% reductions in 
MV
max
, respectively,when compared with SED+SAL, these 
differences were not different from SED + SAL (P > .05). 
Furthermore, SED + DOX MV
max
 was found to be signifi-
cantly lower than TM + DOX and WR + DOX (P < .0 -5). 
MV
mean
 was significantly lower in SED + DOX and W−R + 
DOX when compared with SED + SAL (−38% and 17%, 
respectively, P < .05, Figure 2B), but TM + DOX MV
mean
 
was not found to differ significantly from SED + SAL (−12%, 
P > .05). Additionally, TM + DOX and WR + DOX MV
mean
 
was significantly greater than SED + DOX (P < .05).
Blood flow measurements taken at the aortic valve are 
illustrated in Figure 3. AV
max
 was significantly lower in 
SED + DOX when compared with SED + SAL (−47%, P 
< .05, Figure 3A). However, TM + DOX and WR + DOX 
was not significantly different than SED + SAL AV
max
 (−4% 
and −9%, respectively, P > .05), but TM + DOX and 
WR+DOX AV
max
 was significantly greater than SED + 
DOX (P < .05). AV
mean
 was significantly lower in SED + 
DOX when compared with SED + SAL (−48%, P < .05, 
Figure 3B), but this difference was not seen in TM + DOX 
and WR + DOX (−5% and −14%, respectively, P > .05). 
TM + DOX and WR + DOX AV
mean
 were significantly 
greater than SED + DOX (P < .05).
It is also important to note that in vivo heart rates derived 
from Doppler imaging were found to be significantly differ-
ent between groups. SED + DOX heart rate was found to be 
lower than SED + SAL (302 ± 14 and 390 ± 8 bpm, respec-
tively, P < .05). Exercise preconditioning, however, attenuated 
DOX-induced heart rate reductions as this difference was not 
observed in TM + DOX and WR + DOX (356 ± 10 and 343 ± 
13 bpm, respectively, P > .05).
Isolated Working Heart
Using the isolated working heart model allows for stan-
dardized loading of each heart (ie, preload, afterload, heart 
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rate), and it was observed that SED + DOX possessed 
significantly lower LVDP than SED + SAL,
TM + DOX, and WR + DOX (−22%, −16%, and −19%, 
respectively, P < .05, Figure 4A). Maximal rate of pressure 
development (+dP/dt) was significantly lower in SED + 
DOX when compared with SED + SAL and
WR + DOX (−19% and −15%, respectively, P < .05, 
Figure 4B), and no significant difference was observed 
between TM + DOX and SED + DOX (P > .05). No sig-
nificant group differences were observed with −dP/dt (P 
> .05, Figure 4C).
Myosin Heavy Chain 
and SERCA2a expression
Cardiac MHC is expressed in 2 isoforms (α and β), and 
various forms of cardiac dysfunction (including DOX-
induced cardiotoxicity) are associated with upregulation 
of the β-isoform.3,23 In the present study, LVs from SED + 
DOX expressed 26% β-MHC (with corresponding 74% 
α-MHC), which was significantly different than the 17% 
β-MHC (with corresponding 83% α-MHC) expressed in 
LVs from SED + SAL (P < .05, Figure 5). TM + DOX and 
WR + DOX LVs, however, did not express a significantly 
different MHC isoform expression when compared with 
SED + SAL (21% β-MHC and 21% β-MHC, respectively, 
P > .05). Although treadmill and wheel running provided 
protection against DOX-induced MHC alterations, exer-
cise preconditioning did not provide protection against 
DOX-induced SERCA2a alterations. LVs from SED + 
DOX, TM + DOX, and WR + DOX expressed signifi-
cantly lower levels of SERCA2a than SED + SAL (P < 
.05, Figure 6).
Discussion
The present study reports the protective effects of exercise 
preconditioning on chronic DOX-induced cardiotoxicity. 
Overall, exercise preconditioning (10 weeks of treadmill 
training and wheel running) attenuated DOX-induced car-
diac dysfunction analyzed 4 weeks post–DOX treatment. 
This cardioprotection was associated with preserved β-
MHC expression, but exercise preconditioning did not 
protect against DOX-induced SERCA2a downregulation.
Table 2. M-Mode Derived Cardiac Geometrya
SED + SAL SED + DOX TM + SAL TM + DOX WR + SAL WR + DOX
SWs (mm) 3.06 ± 0.05 2.24 ± 0.13b,c,d 3.11 ± 0.12 2.81 ± 0.09 2.89 ± 0.09 2.73 ± 0.07
SWd (mm) 1.74 ± 0.06 1.28 ± 0.11b,c,d 1.81 ± 0.07 1.73 ± 0.06 1.75 ± 0.06 1.70 ± 0.05
PWs (mm) 3.32 ± 0.08 2.35 ± 0.14b 3.30 ± 0.14 2.61 ± 0.07b 3.18 ± 0.14 2.68 ± 0.08b
PWd (mm) 1.86 ± 0.06 1.26 ± 0.13b,d 1.96 ± 0.08 1.54 ± 0.04b 1.82 ± 0.08 1.68 ± 0.07
LVDs (mm) 3.17 ± 0.17 3.94 ± 0.11 3.37 ± 0.21 3.57 ± 0.17 3.06 ± 0.21 3.68 ± 0.14
LVDd (mm) 6.51 ± 0.15 6.63 ± 0.14 6.75 ± 0.16 6.49 ± 0.27 6.49 ± 0.17 6.52 ± 0.10
RWT (mm) 0.55 ± 0.02 0.39 ± 0.03b,c,d 0.58 ± 0.02 0.55 ± 0.03 0.56 ± 0.03 0.52 ± 0.02
LV mass (mg) 788 ± 36 459 ± 70b,c,d 905 ± 47 745 ± 43 777 ± 31 720 ± 25
Note: SED = sedentary; SAL = saline; DOX = doxorubicin; TM = treadmill; WR = wheel running; SWs = septal wall thickness at systole;  
SWd = septal wall thickness at diastole; PWs = posterior wall thickness at systole; PWd = posterior wall thickness at diastole; LVDs = left 
ventricular dimension at systole; LVDd = left ventricular dimension at diastole; RWT = relative wall thickness; LV = left ventricle.
aData are mean ± standard error of the mean.
bP < .05 versus SED + SAL.
cP < .05 versus TM + DOX.
dP < .05 versus WR + DOX.
Figure 1. Left ventricular fractional shortening of sedentary 
(SED), treadmill trained (TM), and wheel run (WR) rats 
receiving doxorubicin (DOX) or saline (SAL)
*P < .05 versus SED + SAL.
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Doxorubicin Cardiotoxicity
DOX cardiotoxicity is associated with the formation of 
ROS (oxidative stress), which in turn can affect MHC32 and 
SERCA.33 The rat heart expresses primarily the fast 
ATPase activity α-MHC isoform with minimal expres-
sion of the slow ATPase activity β-MHC isoform. Shifting 
of the relative isoform expression toward an increase in β-
MHC (with a corresponding decrease in α-MHC expression) 
may occur during congestive heart failure,34 dilated 
cardiomyopathy,35 diabetic cardiomyopathy,36 and DOX 
Figure 2. Mitral valve blood inflow velocities of sedentary 
(SED), treadmill trained (TM), and wheel run (WR) rats 
receiving doxorubicin (DOX) or saline (SAL)
A, Maximal blood flow velocity. B, Mean blood flow velocity. *P < .05 versus 
SED + SAL; †P < .05 versus TM + DOX; ‡P < .05 versus WR + DOX.
exposure.3,21,22 This MHC shift is associated with significant 
impairments in cardiocyte sliding filament velocities37 and 
power outputs38,39 as well as LV pressure development.40 
In addition to ROS-related MHC disturbances, DOX 
impairs myocardial energetics by accumulating in and dis-
rupting mitochondria.41 The result is impaired mitochon-
drial function and altered ATP production, which has been 
shown to promote a shift in the cardiac MHC profile.42 A 
shift toward the β-isoform results in a more metabolically 
efficient cardiocyte; however, this energy preservation 
comes at the cost of systolic function.
Figure 3. Aortic valve blood outflow velocities of sedentary 
(SED), treadmill trained (TM), and wheel run (WR) rats 
receiving doxorubicin (DOX) or saline (SAL)
A, Maximal blood flow velocity. B, Mean blood flow velocity. *P < .05 versus 
SED + SAL; †P < .05 versus TM + DOX; ‡P < .05 versus WR + DOX.
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Figure 4. Isolated working heart left ventricular (LV) function 
of sedentary (SED), treadmill trained (TM), and wheel run (WR) 
rats receiving doxorubicin (DOX) or saline (SAL)
A, Developed pressure. B, Maximal rate of pressure development (+dP/
dt). C, Maximal rate of pressure decline (−dP/dt). *P < .05 versus SED + 
SAL; †P < .05 versus TM + DOX; ‡P < .05 versus WR + DOX.
Figure 5. β-Myosin heavy chain expression, with representative 
gel scans, in left ventricular homogenates from sedentary (SED), 
treadmill trained (TM), and wheel run (WR) rats receiving 
doxorubicin (DOX) or saline (SAL)
The upper band on the gel scan is the α-isoform and the bottom band is 
the β-isoform. *P < .05 versus SED + SAL.
Figure 6. Sarcoendoplasmic reticulum calcium ATPase 2a 
(SERCA2a) expression, with representative blots, in left 
ventricular homogenates from sedentary (SED), treadmill trained 
(TM), and wheel run (WR) rats receiving doxorubicin (DOX) or 
saline (SAL)
*P < .05 versus SED + SAL.
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In the present study, DOX promoted β-MHC upregula-
tion with concomitant α-MHC downregulation, and this 
altered MHC profile was associated with systolic dysfunc-
tion in the form of reduced aortic blood flow velocities, 
LVDP, and +dP/dt. Systolic dysfunction with DOX treat-
ment is a common clinical concern as ejection fraction is 
often times measured throughout treatment to assess the 
degree of cardiotoxicity.18 However, the issue of chronic car-
diotoxicity is equally concerning because debilitating car-
diac dysfunction may set in months or years following 
treatment even though severe cardiac dysfunction was not 
detected during treatment.43 Long-term cardiac remodeling 
as a result of the DOX insult may be more of a concern 
than the acute changes occurring immediately following 
DOX administration because of the fact that it may be clini-
cally diagnosed as dilated cardiomyopathy or heart failure.
Left ventricular morphology in the current study was 
also significantly altered 4 weeks following DOX treat-
ment. Reductions in LV wall thickness, mass, and FS were 
evident, and taken together, these changes suggest myocar-
dial wasting which could be explained, at least partly, by 
apoptosis. Apoptosis is one of the many mechanisms 
contributing to DOX cardiotoxicity,44-46 and although indi-
ces of apoptosis were not analyzed in the present study, it is 
possible that apoptotic pathways were activated, which may 
have led to programmed cell death since DOX administra-
tion can increase both intrinsic and extrinsic apoptotic path-
way activities.47 Cell death, in this regard, may have 
contributed to the reduced wall thickness and LV mass 
observed with DOX-treated hearts.
DOX cardiotoxicity has also been attributed to cardiac 
Ca2+ homeostasis interruptions,48,49 and it has been reported 
that DOX treatment downregulates expression of key Ca2+ 
handling proteins such as ryanodine receptor, calsequestrin, 
Na/Ca exchanger, phospholamban, SERCA2a, and 
SERCA2b.26,50 In the current study, we analyzed SERCA2a 
expression as it is the primary SERCA isoform expressed 
in cardiac cells and therefore responsible for the majority 
of sarcoplasmic reticulum (SR) Ca2+ reuptake. Efficient 
pumping of Ca2+ from the cytosol to the SR is critical in 
cardiocyte relaxation, and one hallmark of DOX cardio-
toxicity is diastolic dysfunction.51,52 The current study 
reports DOX-induced diastolic dysfunction in the form of 
reduced mitral valve blood flow velocities with associ-
ated downregulation of SERCA2a.
Exercise Cardioprotection
Exercise preconditioning has been shown previously to 
attenuate early-onset DOX cardiotoxicity.2,3,53,54 
However, in these studies, cardiotoxicity was analyzed 1 
to 10 days post–DOX administration, and until the cur-
rent study, it was unclear how long the protective effects 
of exercise preconditioning against DOX cardiotoxicity 
could persist. Exercise preconditioning in the current 
study protected against DOX-induced SW thinning, LV 
mass reduction, FS decline, mitral and aortic blood flow 
decrements, LVDP reduction, and +dP/dt decline.
Since DOX cardioxicity involves the generation of ROS, 
many studies examining the cardioprotective effects of 
exercise have focused on oxidative stress and antioxidants. 
DOX-induced oxidative stress has been shown to cause cel-
lular damage in the form of lipid peroxidation and protein 
carbonylation both of which are ameliorated with exercise 
preconditioning.53,54 Kanter et al28 reported that exercise 
training prior to and during DOX treatment was associated 
with increased antioxidant activities (catalse, glutathione 
peroxidase, and superoxide dismutase) in blood and liver of 
mice, but this degree of antioxidant upregulation was not 
observed in the heart. Likewise, exercise-induced cardio-
protection has been shown previously to not necessarily be 
the result of antioxidant upregulation.2,54 Although cardiac 
antioxidant upregulation was not evident in these exercise 
training studies at the time of myocardial analysis (ie, 1 and 
5 days post DOX), it is possible that antioxidant activity/ 
expression was increased at the time of DOX administra-
tion, which potentially provided protection against the ini-
tial insult of DOX.
One of the key findings of the current study was that 
exercise-induced preservation of the MHC isoform distri-
bution was evident 4 weeks after completing DOX treat-
ment even though the animals remained sedentary during 
the 4-week post-DOX period. The preservation of LV MHC 
isoform distribution 4 weeks post-DOX in exercise precon-
ditioned rats is similar to the degree of preservation 
observed in an earlier report in which the MHC isoform 
distribution was measured 5 and 10 days post–DOX treat-
ment.3 This preservation of MHC expression may explain 
the attenuated systolic dysfunction observed in exercise pre-
conditioned rats since relative α- and β-MHC expression 
has a dramatic impact on cardiac function.38,39 Exercise 
training has a profound effect on MHC expression as illus-
trated by Jin et al,55 who reported that 13 weeks of progres-
sive exercise training substantially increased α-MHC 
mRNA. In fact, of the genes analyzed in the study by Jin et 
al,55 α-MHC was the only one found to be significantly 
increased. It is possible that a training-induced upregula-
tion of α-MHC mRNA in the current study provided protec-
tion against the initial insult of DOX, which typically 
promotes a decrease in α-MHC expression. This is sup-
ported by evidence that significantly altered MHC expres-
sion has been detected just hours after DOX administration.56 
The duration of the cardioprotective effects of exercise 
observed in the present study may in fact be related to the 
preconditioned heart being resistant to the acute DOX 
exposure thereby minimizing the chronic cardiotoxicity. 
This concept has been illustrated clinically by studies indi-
cating that the severity of DOX-induced early-onset cardiac 
dysfunction has been used to predict the severity of chronic 
cardiac dysfunction.43
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The lack of SERCA2a preservation in exercise precon-
ditioned hearts in the current study is also worthy of note. 
Despite significantly lower SERCA2a expression when 
compared with sedentary controls, hearts from precondi-
tioned animals receiving DOX had significantly better dia-
stolic function than hearts from sedentary animals 
receiving DOX (ie, maximal and mean mitral blood flow 
velocities). Although SERCA2a is primarily responsible 
for the Ca2+ reuptake into the SR, which is involved in 
cardiocyte relaxation, it is possible that other mecha-
nisms may have been responsible for the preserved dia-
stolic function observed in hearts from exercise 
preconditioned DOX-treated animals. One major mecha-
nism contributing to DOX-induced cardiac dysfunction is 
cytosolic Ca2+ overload, and downregulation of SERCA2a 
contributes to Ca2+ overload-induced dysfunction.57 
However, reduced SERCA2a expression in models of car-
diac dysfunction may be a compensatory mechanism,58 
and SERCA2a deficiency is not necessarily associated 
with reduced cardiac performance.59 Additionally, DOX 
has been shown to alter other Ca2+ handling proteins such 
as ryanodine receptor, calsequestrin, and Na/Ca exchanger 
resulting in altered Ca2+ handling, and this disruption con-
tributes to DOX cardiotoxicity.26,50 Exercise has been 
shown to have a positive impact on overall cellular Ca2+ 
translocation,60,61 and future investigations should focus 
on the interaction of DOX and exercise on additional Ca2+ 
translocation mechanisms.
Conclusion
These data demonstrate that 10 weeks of exercise precon-
ditioning was cardioprotective against DOX cardiotoxicity. 
Interestingly, this cardioprotection was observed 4 weeks 
after the conclusion of DOX treatment even though the 
animals were sedentary during the 4-week period. 
Cardioprotection was associated with preserved in vivo and 
ex vivo cardiac function, preserved MHC isoform distribu-
tion, and was evident regardless of mode of activity (tread-
mill/wheel running). This suggests that exercise stress level 
was not a major factor in the degree of protection as volun-
tary wheel running has been shown to be less stressful than 
motorized treadmill running.62 This study provides further 
insight into the effects of exercise and DOX cardiotoxic-
ity by demonstrating that exercise preconditioning can pro-
tect against DOX-induced cardiac dysfunction for up to 4 
weeks after exposure (early chronic cardiotoxicity), and that 
exercise during the post-DOX period is not a requisite to 
maintain the cardioprotective effects.
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